SCHEMBL2180318

SCHEMBL2180318

COc1ccc(C(=O)Nc2ccc(-c3ccc4c(c3)CN(C(C(=O)O)C(C)C)C4=O)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.57
LMNA P02545 2/20 0.57
PLAU P00749 1/20 0.47
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
ALOX15 P16050 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
MAPT P10636 3/20 0.45
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 3/20 0.45
NR4A1 P22736 1/20 0.45
MCL1 Q07820 1/20 0.45
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45
KDM4E B2RXH2 1/20 0.45
HPGD P15428 1/20 0.45
MEN1 O00255 2/20 0.44
SDCBP O00560 2/20 0.44
SDC2 P34741 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2181127 1.00 TP53 (0.57) TP53LMNAPLAURAB9ANPC1
SCHEMBL2180197 0.93 TP53 (0.57) TP53LMNAPLAURAB9ANPC1
SCHEMBL2180067 0.93 TP53 (0.57) TP53LMNAPLAURAB9ANPC1
SCHEMBL2178532 0.92 LMNA (0.60) TP53LMNARAB9ANPC1SMN1; SMN2
SCHEMBL2180785 0.92 LMNA (0.60) TP53LMNARAB9ANPC1SMN1; SMN2
SCHEMBL2179942 0.90 LMNA (0.58) TP53LMNASMN1; SMN2MAPTKMT2A
SCHEMBL2179936 0.90 LMNA (0.58) TP53LMNASMN1; SMN2MAPTKMT2A
SCHEMBL2180871 0.90 SDCBP (0.46) TP53LMNARAB9ANPC1SMN1; SMN2
SCHEMBL2178684 0.90 SDCBP (0.46) TP53LMNARAB9ANPC1SMN1; SMN2
SCHEMBL2180086 0.89 LMNA (0.49) TP53LMNASDCBPSDC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT TP53 2093/4885LMNA 2193/4885PLAU 1279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.